Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- (-) Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- (-) Regulatory Barriers & Challenges
- Understanding Health Spending
- (-) Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 65 Results
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance
Published in the Journal of Managed Care and Specialty Pharmacy, this study found that low-income and non-white individuals participating in commercial health plans have lower usage of specialty…
Guiding Practices for Patient-Centered Value Assessment (2024)
NPC has updated its Guiding Practices for Patient-Centered Value Assessment. This update of NPC's guiding practices for US value assessment will help inform the growing importance of this tool to…
Medicaid Best Price Reforms Can Encourage Innovative Payment Arrangements for Chronic Therapies
This NPC study extends previous work analyzing reforms to CMS’ Medicaid Best Price reporting rules to encourage the uptake of value-based purchasing agreements for chronic disease treatments.
ICER Misses…Again
The latest Unsupported Price Increase Report from ICER lacks balance, uses flawed methods and may harm patients.
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and…
Achieving “Fair Access” Requires Better Benefit Design
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
Creating a Dialogue or Just Playing for Headlines? Third Time Isn’t the Charm for ICER’s Pricing Report
Selectively picking the data to arrive at a convenient narrative — like the Institute for Clinical and Economic Review does in its third drug pricing report — should not be mistaken for good…
Chairman’s Blog: Five Questions Decision-Makers Should Be Asking About Health Technology Agencies
NPC Board Chair and BMS SVP Michael Ryan advises caution and careful consideration of the potential risks and tradeoffs for patients by using a centralized, government-run health technology…
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
Stakeholders Find Step Therapy Should Be Evidence-Based, Flexible and Transparent: Assessing Appropriateness Using a Consensus Approach
Stakeholders disagree on when step therapy is appropriate, but agree on a set of criteria about how to develop, implement, communicate, safeguard and evaluate step therapy protocols.
If You Must Do Step Therapy, Do It Right
Finding consensus among health care stakeholders is never easy, and that is certainly true when it comes to the use of care management tools. But there are areas of agreement, especially if we focus…
ICER Pricing Report: Creating a Dialogue or Just Playing for Headlines?
Given declines in drug prices, the Institute for Clinical and Economic Review’s second report on drug pricing – focusing on a hand-picked, narrow group of medicines rather than the overall landscape …
Empowering the Patient Voice in Value Assessment: Paving the Way for MCDA
The National Health Council (NHC) and National Pharmaceutical Council (NPC) co-hosted a webinar that explored how multi-criteria decision-making analysis (MCDA) can be used in value assessment.
Multi-Criteria Decision Analysis: Can It Help Make Value Assessment More Patient Centered?
This white paper identifies good practices and key considerations for integrating the patient voice into patient-centered multi-criteria decision analysis.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
IVI's Jennifer Bright on Value Assessment and Transparency
In an interview, Innovation and Value Initiative Executive Director Jennifer Bright discusses how her organization has been advancing value assessment practice and the key priorities to make the…